title: Interleukin-6 gene promoter -174G/C polymorphism and insulin resistance: a pilot study.
abstract: BACKGROUND
  The aim of this pilot study was to evaluate the relationship between interleukin-6 promoter -174G/C (IL-6 -174G/C) polymorphism and insulin resistance (IR) in obese patients with coronary heart disease (CHD).
  
  
  METHODS
  Twenty obese male patients with CHD were selected from a larger database of patients (n=606). IL-6 -174G/C genotype was previously analysed and only homozygotes with the CC genotype (n=10) or GG genotype (n=10) were selected. IR was measured using the homeostasis model assessment for IR (HOMA-IR) method.
  
  
  RESULTS
  Differences in age, body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), hypertension, IL-6, C-reactive protein and HOMA-IR were not significant between the genotypes (p>0.05), but analysis of a homogeneity-of-slopes model showed that genotype had a significant influence on HOMA-IR (p=0.037), and the interaction between genotype and HDL-C had a pronounced tendency to affect HOMA-IR (p=0.058). Using multiple regression analysis, we found that HDL-C had a significant effect on HOMA-IR (p=0.023), and TG had a tendency to affect HOMA-IR (p=0.066) only in the CC genotype.
  
  
  CONCLUSIONS
  Our data show that IL-6 -174G/C polymorphism may have a significant effect on IR. A comparison between the effects of various cardiovascular risk factors showed that HDL-C may have a significant effect on HOMA-IR in the CC genotype but not in the GG genotype. Further research is needed to test the preliminary results.
authors.affiliation: Institute of Experimental and Clinical Medicine, University of Latvia, Riga, Latvia. tretjako@latnet.lv
authors.forename: Peteris
authors.initials: P
authors.lastname: Tretjakovs
authors.forename: Gustavs
authors.initials: G
authors.lastname: Latkovskis
authors.forename: Normunds
authors.initials: N
authors.lastname: Licis
authors.forename: Dace
authors.initials: D
authors.lastname: Juhnevica
authors.forename: Antra
authors.initials: A
authors.lastname: Jurka
authors.forename: Inga
authors.initials: I
authors.lastname: Bormane
authors.forename: Juris I
authors.initials: JI
authors.lastname: Aivars
authors.forename: Agnis
authors.initials: A
authors.lastname: Stifts
authors.forename: Valdis
authors.initials: V
authors.lastname: Pirags
mesh_terms: D000367:Age Factors; D000368:Aged; D002318:Cardiovascular Diseases / Q000473:pathology; D008076:Cholesterol, HDL / Q000378:metabolism; D003327:Coronary Disease / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D007333:Insulin Resistance; D015850:Interleukin-6 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009765:Obesity; D010865:Pilot Projects; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012307:Risk Factors
chemical_list: D008076:Cholesterol, HDL; D015850:Interleukin-6